CANTOS study showed that anti-inflammatory therapy targeting the IL-1β with canakinumab in patients with a stable coronary disease could lead to a 15% lower risk of cardiovascular events than was observed with placebo, but also led to a slightly higher incidence of fatal infections (34). The gene discussed is IL1B; the disease is coronary artery disorder.